Envista Lifts 2026 Guidance as Q3 Buyback and Cash Flow Details Emerge
NVST sits 45% above its 52-week low of $18.77 on elevated volume (2.1× avg).
Summary
Envista raised its full-year 2026 earnings guidance alongside third-quarter results, though the release did not disclose the revised figures. Q3 sales were USD 691.5 million versus an IBES estimate of USD 688.7 million. Q3 headline numbers were distorted by a $428M operating profit and $2.62 diluted EPS from foreign currency translation gains — non-cash items that did not affect adjusted results. Cash generation softened: operating cash flow was $78M versus $79M a year ago and free cash flow $63M versus $68M. The company repurchased 386K shares for about $10M, leaving roughly $273M of capacity on its buyback program. The guidance raise is the real change to the story; the translation gain should be stripped out when judging underlying performance.
At the time of this announcement, NVST was trading at $27.19 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $18.77 to $30.42. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.